PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER (PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER).
PRISMASOL BGK 4/3.5 is a hemofiltration solution. It provides electrolytes, buffer (bicarbonate), and glucose to replace fluid and electrolyte losses during continuous renal replacement therapy (CRRT). The solution composition maintains fluid and electrolyte balance, and the bicarbonate buffer helps correct metabolic acidosis. It does not have a classic pharmacological mechanism.
| Metabolism | Not metabolized; components are excreted or utilized by the body. Glucose is metabolized via normal pathways. |
| Excretion | PRISMASOL BGK 4/3.5 is a hemodialysis solution; its components (electrolytes, buffer) are eliminated based on patient's renal function and dialysis clearance. For example, potassium is primarily excreted renally (90%) with minor fecal loss (10%); bicarbonate is converted to CO2 and exhaled (lungs) or renally excreted; chloride follows renal excretion. As the solution is administered during continuous renal replacement therapy (CRRT), the exogenous solutes are removed via the hemodialysis filter, with the percentage of elimination dependent on the dialysis dose and patient's residual renal function. In anuric patients, essentially 100% of the infused solution's components are eliminated via the dialysis circuit. |
| Half-life | The components of PRISMASOL BGK 4/3.5 do not have a classical half-life as they are infused continuously during CRRT. The elimination of electrolytes and buffer is governed by the dialysis prescription and the patient's metabolic rate. For instance, the half-life of exogenous bicarbonate is negligible as it rapidly equilibrates with the body's bicarbonate pool; in contrast, the half-life of potassium during CRRT is typically 2-4 hours depending on the dialysate flow rate and the patient's potassium distribution. However, for the solution itself, its 'half-life' is not applicable. |
| Protein binding | The individual components of PRISMASOL BGK 4/3.5 (sodium, potassium, calcium, magnesium, chloride, bicarbonate/lactate) are not significantly protein-bound. For electrolytes, protein binding is minimal (e.g., calcium is about 40-45% bound to albumin, but this is endogenous; the infused ionic calcium is free). Bicarbonate and lactate are not protein-bound. Therefore, overall protein binding is <10%. |
| Volume of Distribution | The apparent volume of distribution (Vd) for the solution's components is not a single value, as each electrolyte distributes differently. For example, sodium has a Vd of approximately 0.5-0.6 L/kg (extracellular fluid), potassium has a Vd of about 4-5 L/kg (total body water with predominance in intracellular space), and bicarbonate distributes in the extracellular fluid (~0.3 L/kg). Clinically, the Vd indicates that the infused solution initially expands the extracellular compartment, with subsequent distribution into the intracellular space for some ions (e.g., potassium). |
| Bioavailability | Bioavailability is 100% via the intravenous (IV) route, as the solution is administered directly into the bloodstream through the dialysis circuit. There is no first-pass metabolism. For other routes, bioavailability is not applicable (0% orally, as the solution is not intended for oral use). |
| Onset of Action | The onset of action for PRISMASOL BGK 4/3.5 is immediate upon initiation of CRRT. Correction of electrolyte imbalances and acid-base disturbances begins within minutes as the dialysis circuit removes waste products and replaces buffers. For example, serum potassium levels start decreasing within 15-30 minutes of starting CRRT. |
| Duration of Action | The duration of action is equivalent to the duration of the CRRT session, as the solution's effects on serum electrolyte and acid-base status are maintained only while the infusion is ongoing. Once CRRT is discontinued, the effects cease; however, corrections may persist depending on the patient's renal function and ongoing losses. Typically, a CRRT session lasts 24 hours or longer, and the solution is continuously delivered. |
Continuous renal replacement therapy (CRRT) solution: Administer via central venous access at flow rates typically 1500-4000 mL/h, adjusted to achieve desired electrolyte and acid-base balance. Not directly administered; used as replacement or dialysis fluid.
| Dosage form | INJECTABLE |
| Renal impairment | Not applicable; product is indicated for use in acute kidney injury requiring CRRT. Dosing adjustments are inherent in the CRRT prescription based on patient metabolic needs and clearance. |
| Liver impairment | No specific Child-Pugh based dose adjustment; monitor for metabolic alkalosis or citrate accumulation in severe hepatic impairment. Use with caution. |
| Pediatric use | Weight-based CRRT flow rates: Initial rate 2000-4000 mL/h/1.73 m², adjusted for age and weight. Typical rate 2000-3000 mL/h for children >20 kg. Use with citrate anticoagulation monitoring. |
| Geriatric use | Use standard CRRT dosing; monitor for fluid overload and electrolyte disturbances due to age-related renal and cardiovascular changes. Adjust flow rates cautiously. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER (PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER).
| Breastfeeding | Excreted in milk in negligible amounts due to composition (electrolytes, glucose). M/P ratio not applicable. Considered compatible with breastfeeding; monitor infant electrolyte levels if concern. |
| Teratogenic Risk | No evidence of teratogenicity; used as continuous renal replacement therapy fluid. First trimester: Minimal fetal exposure; no known risk. Second trimester: No adverse effects reported. Third trimester: No specific risk; monitor electrolyte balance. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component of the solution.","Severe uncorrected electrolyte imbalances.","Alkalosis where correction of acidosis is not required.","Severe glucose intolerance or hyperglycemia uncontrolled with insulin (relative)."]
| Precautions | ["Do not administer intravenously without use in CRRT circuit.","Use only with appropriate CRRT equipment.","Monitor serum electrolytes, acid-base balance, and glucose levels.","Risk of hyperglycemia in diabetic patients due to glucose content.","Risk of electrolyte disturbances if not properly prescribed.","Must be sterile and pyrogen-free."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal serum electrolytes (sodium, potassium, magnesium, calcium, bicarbonate), glucose, acid-base status, and fluid balance. Fetal monitoring: assess for signs of electrolyte imbalance or edema via ultrasound if clinically indicated. |
| Fertility Effects | No known effects on fertility; data limited. Potential indirect effects due to underlying renal condition. |